Liz Gehl: Sourcing Talent for the Cannabis Industry

Liz Gehl is the founder and CEO of Gehl Search Partners, a talent recruitment firm that specializes in finding qualified personnel for highly regulated industries with a focus on positions in sales, marketing, strategy and planning, compliance, finance, accounting, and administrative roles.

We recently caught up with Liz for an interview about what makes a good cannabis industry employee and how her firm helps entrepreneurs find the right team. We hear a little about her process for cannabis industry recruitment, what lessons the cannabis industry ought to learn from other industries, and more! Read the full interview below.


Ganjapreneur: Could you sum up the role that Gehl Search Partners takes on when you work with a cannabis company?

Liz Gehl: We provide mid to senior level talent that can’t typically be found by posting a job ad or similar methods. We do our due diligence early in the process by building deep relationships with those we work with. The more we know about our client’s product or service and what drives them day in and day out, the more successful we are in our ability to represent their company in a meaningful way that resonates with the ‘right’ candidates. Our business has been and will continue to be very relationship driven. Our long-standing relationships have always been the best source of highly qualified talent for us. Talented people know other talented people and aren’t always willing to work for or with just anyone; they want to ensure there is a genuine sense of trust there. That when a recruiter is telling them about a company or role, it is not a sales pitch, more so a clear picture of what it will be like to work there. Spending over 10 years cultivating these relationships in multiple industries allows us to know the right people, or, know the right strategy in attracting them quickly. As barbaric as the term may sound, we truly are headhunters.

When did you decide to begin working with cannabis companies?

Shortly after opening my firm. Personally, I’ve been a medicinal cannabis patient for many years. I’ve never fit the stigma of what a “marijuana patient” was. I’ve always been a very driven woman working in human resources and recruiting. Passionate about the benefits of cannabis and knowing that there are a lot of other driven and professional men and women out there working in various industries who are afraid to speak up due to the risk of losing their job or feeling judged, I feel that it is important to continue to bring that level of professionalism into the cannabis industry. The amount of incredibly intelligent people already working in cannabis is astounding. The general public needs to see more of that. Also, by bringing in talent from outside industries to the cannabis industry, I feel that we will be able to grow the industry at a far more rapid rate.

What sorts of qualities do you think are especially important for somebody to work in the cannabis industry?

I personally think that those who are most successful and happy in their jobs are those who have a true passion for the benefits of the plant. Regardless of what many think, this is not an industry to work in if you want to get rich quick. It is still somewhat volatile. Rules and regulations continue to change, as we all know, so being nimble, resiliant, and adaptable are some of the key attributes we look for.

In general, what’s the most difficult part of finding talent for the cannabis space — and what’s the easiest part?

I’ll start with what is most challenging; many companies are still in startup mode so salary ranges are lower than they are for other industries (in most cases). Candidates, many times feel that there is a ton of money in the cannabis industry. I spend a lot of time counseling candidates on their salary expectations; digging through to find those who really want to be a part of building a business, not just for the monetary gain, but for the experience.

The easiest part is finding passionate, intelligent, down to earth people who truly want to make a difference. Many times, the empathy and sense of community shines through when you are speaking to those who have worked in the industry for a long time.

What are some of the biggest misconceptions about the hiring/talent hunting process?

The biggest misconception by hiring companies I’ve found is that relatives or friends make the best employees. Don’t get me wrong, sometimes this does work out, however, the most successful companies in any industry are those who hire a diverse employee base; employees who bring varying skill sets and who think differently than those who are directly and personally involved in the decision making process. Personal relationships are tough enough, but throw in a supervisor/subordinate type of reporting structure and things can get really squirrely. Senior leaders who aren’t afraid to challenge ownership and bring new out of the box ideas, most frequently come from outside of their inner circle. The risk of losing a friend isn’t there, thus the focus is solely on growing revenue and market share and doing what is best for the company’s long term strategy.

What would you say are the most important factors behind an executive’s placement in cannabis?

For the candidate, the understanding that this is not an industry where you will get rich quick, at least not for most of us. In my experience, I’ve found that those who truly believe in the benefits of cannabis and want to be part of building something big, even if it goes against the status quo, are most successful. I’ve had candidates take significant pay cuts in salary with the understanding that they are on the forefront of a new industry and they are willing to take a calculated risk in order to progress the industry forward and hope that their career will as well. Most are granted substantial amounts of equity, but that is a risk. Obviously given what I do for a living, I understand this is a tough choice for many. We spend a significant amount of time getting to know our candidates to ensure this life decision is one that is comfortable to them, and the “risk” makes sense in the long term strategy of their career goals. With the client or hiring companies, we do the same due diligence; does this company have a clear goal and path to success? Is it a sustainable company where growth and profitability are not only achievable but likely? Once I am confident that all of the above align, a successful candidate/client match is easily found, and it is a long term fit rather than a quick fix.

What lessons can the cannabis industry learn from other highly regulated industries you work in?

The largest lesson, in my opinion, is that compliance is incredibly important in all aspects of your business. There are so many parallels with the alcohol industry and compliance is a big one. There are varying laws in each state from distribution to delivery (or direct to consumer) to what is considered “safe” growing or manufacturing practices. Given that cannabis is held to the most strict compliance laws we have ever seen, I think the two industries can learn an incredible amount from each other. Why should the cannabis we consume be held to stricter guidelines for safety than the beer we drink? By collaborating I think both industries can bring the transparency necessary to progress forward collaboratively rather than competitively.

What’s your advice for somebody who wants to be discovered and hired in the cannabis industry?

Reach out and build connections! Educate yourself if you are brand new to cannabis, regardless if you are a consumer or not, the education will pay off as there is so much for all of us to learn. Set yourself apart if you are a consumer. There are many, many cannabis consumers out there who are dreaming of a job where there can smoke or vape at work. Show who you are as a professional, what skills you have that bring value to the company and the industry, what you can do to help the industry out of the shadows of the “stoner” culture. That is what my clients are looking for-incredibly talented, skilled professionals who don’t necessarily fit the pot head stereotype, but have a deep understanding of the plant and its benefits.


Thank you, Liz, for taking the time answer our questions! To contact or learn more about Liz Gehl, you visit her company website at GehlSearchPartners.com or email info@gehlsearchpartners.com.

End


Edmonton, Alberta City Committee Recommends Allowing Public Cannabis Consumption

On Wednesday, the Edmonton, Alberta city community and public services committee agreed to rules allowing the smoking of cannabis in outdoor public spaces like parks and sidewalks, the CBC reports. Cannabis smokers in outside spaces would conform to similar rules as tobacco smokers, remaining 10 meters away from doors and open windows and 30 meters away from areas for children such as playgrounds. Smoking would also be prohibited on restaurant patios and at places like schools and event venues.

The committee had the choice of classifying cannabis more like alcohol, with strict controls on consumption, but chose to support more relaxed rules. City Councillor Ben Henderson supported the decision, pointing out that there would likely be unintended consequences regardless of which ruleset the committee chose.

“If we make it too restrictive about where people can use it … then where are people going to partake of a substance that presumably will be legal shortly?” — Ben Henderson, to the CBC

Another City Councillor, Michael Walters, disagreed with the recommendations. Walters doesn’t support smoking on public sidewalks and recreation fields and said he’s seen no evidence in other jurisdictions of stricter rules resulting in unintended consequences. Some businesses on Whyte Avenue, one of Edmonton’s major shopping and tourism areas, are also concerned that second-hand smoke will scare away customers during the summer months when most businesses leave their doors open.

Chris Hansen, however, owner of the “On Whyte” tobacco shop thinks policing the ability to smoke on sidewalks would be difficult.

“If we’re going to start regulating the smells that walk by on Whyte Avenue, it will become a much less busy street.” — Chris Hansen, to the CBC

The committee’s Wednesday decision is not the final word on the matter. The council can still make amendments to the bylaw during its July 4th meeting.

End


The dusk skyline of downtown Portland, Oregon.

Non-Cannabis Sourced CBD Cafe Opens in Portland, Oregon

A cafe serving drinks and chocolate infused with CBD not extracted from cannabis plants has opened in Portland, Oregon, according to local news outlet KATU.

The cafe is owned and operated by Grön Chocolate, an existing licensed edibles manufacturer in Oregon. The cafe sources CBD from evergreen tree bark from southeast Asia — not from cannabis or hemp — so that it can remain unregulated by the Oregon Liquor Control Commission.

Most cannabidiol research has been performed using cannabis-extracted CBD; there have not been any studies on CBD extracted from other plants. Grön says the effect from this type of CBD is different.

“We’re able to actually go out to the public with this product because it’s not from cannabis or hemp. We can do public medicated samples and people can try it for themselves.” — James Sharinghousen, Grön CBD’s Event Coordinator, via KATU

Grön has been manufacturing cannabis chocolates for three years but, due to Oregon regulations, they can’t effectively market their products at fairs or events. Federal regulations also prohibit them from shipping their cannabis-derived products across state lines. They hope the new cafe attracts customers who may have been hesitant to go into a dispensary to try their normal products. Because the CBD products at this cafe are produced without cannabis, Grön will also be able to ship to customers outside of Oregon.

The Oregon Liquor Control Commission says it has no plans to try and regulate the cafe, though Grön’s Operations Manager Jenna Rice knows that may change.

“That’s not to say somebody couldn’t come in tomorrow and tell us something different. We’re definitely aware that could happen.” — Jenna Rice, Grön’s Operations Manager, via KATU

More CBD cafes may be opening soon as the Oregon Liquor Control Commission is set to craft rules regarding industrial hemp in the next few months.

End


Cy Scott: Headset, Business Intelligence Platform

Cy Scott: How Data Can Help Startups Navigate Emerging Cannabis Markets

It has been nearly four years since adult-use cannabis legislation took effect in Washington and Colorado, and in that time the market landscape has evolved and shifted at breakneck speed. As emerging markets in California, Canada, and elsewhere begin to take off, entrepreneurs are bound to face even greater obstacles and competition. While the first wave of cannabis entrepreneurs had to go to market essentially blind, founders and investors in new markets will now have the ability to make some level of predictions based on what has transpired.

In this special edition of the Ganjapreneur podcast, Headset co-founder and CEO Cy Scott joins Ganjapreneur co-founder and COO Noel Abbott for a conversation about how the adult-use industry has matured over the past few years, and what entrepreneurs in emerging markets can learn from the market data that now exists. The interview covers a lot of useful information for growers who are planning their go-to-market strategy, and Cy provides some great suggestions about how to use data to help drive decision-making. Headset is a business intelligence platform that provides cannabis producers and retailers the ability to easily analyze and interpret their own business data and see how it fits into the bigger picture of the market.

Listen to the podcast episode or read along with a full transcript below! For another deep-dive into cannabis industry data, check out our previous episode with Headset focused on consumer trends and purchasing behavior in the Washington market.


Listen to the Podcast:


Read the Transcript:

Noel Abbott:  Hi there. I’m Noel Abbott, Chief Operating Officer of Ganjapreneur.com and you are listening to the Ganjapreneur podcast where we speak directly with cannabis business owners, activists and industry stakeholders. Today I’m back in Seattle, Washington for another special onsite edition of our podcast at Headset, a market data and business intelligence platform for cannabis industry business owners. Today I’m joined by Headset’s co-founder and CEO, Cy Scott who is also one of the original co-founders of the website Leafly. Thanks for having me back, Cy. How are you?

Cy Scott:  Yeah. Great Noel. Thanks, happy to be back.

Noel Abbott:  Awesome. This is the third episode that I’ve come down here to record with Headset, and for anyone who’s hearing this for the first time, I recommend you checking out the two episodes that we’ve already recorded, the first of which focused on the experience of bootstrapping Leafly, one of the most successful websites related to cannabis in the world, and we had all three of the founders: Brian Wansolich and Scott Vickers were here as well. And then the second episode focused on consumer demographics and purchasing behavior and appealing to consumers in the Washington market. So, definitely check those out if you haven’t already.

I’m really excited to get into today’s conversation because I want to dig into the big question that is facing, I would imagine, just about every entrepreneur in the cannabis industry. And that is, how can I make sure that I’m maximizing my chances for survival in this market to build a company that sustains itself and that will grow and thrive in the future in spite of so many obstacles and so much volatility?

Ahead of this interview I’ve asked you to take a look at the data that Headset has aggregated and the experience that you have working directly with producers and retailers as the market has evolved and to see if you can come up with some surface-level impressions and predictions that can help business owners in emerging markets like California and Canada and other places that are opening up, to help them plan for the future. So, before I get into the details of all of that and for anyone who may not have listened to the previous episodes yet, could you give me a quick overview of the scope of the data that we’re looking at and how it was gathered?

Cy Scott:    Sure. Headset is a data and analytics company. Our mission is to help cannabis operators take a lot of the guesswork out of business decisions by leveraging data. We are able to get that data by working pretty closely with retailers, so we work directly with them, connecting to their point-of-sale systems. We give retailers business intelligence, so a good sense of what’s going on with their own internal data, sales trends, better understanding their inventory carry, what their bud tenders are selling and so on. We’re also able to benchmark against kind of market averages so they know, you know, how they’re performing and then what we do is we actually look at all those transactions in aggregate, so we anonymize, aggregate and classify and code those products to get a sense of what’s happening across a broader market from a consumer transaction angle, and so the data that we’re going to be talking about today is kind of our Washington State data. You know, right now we’re processing about 75% of every dollar that transacts in Washington. We’ve got a very significant footprint here with retailers. It was our first market. It’s our backyard given that we’re in Seattle. That said, we are in a number of other markets as well including Colorado, Nevada and Oregon. We’ll be launching our California and Canada insights later this year. Excited for that.

What’s really cool and exciting about Washington is that it’s one of two relatively mature markets given Washington and the Colorado market both legalized at the same time. You know, one of the interesting things about Washington is that they took the model, the dispensary model and kind of threw it out the window and started from scratch. It’s really interesting to kind of see this industry develop from zero to one as they say. Where Colorado had a very mature medical market with a lot of traceability, so they were able to kind of convert that into adult use, so it had a lot of legacy medical side. You know, what’s interesting is Washington has been in operations now for three solid years. More than that, but we have, you know year-over-year data across three years. So, we’re starting to recognize some really cool trends. I think you said it great, as indicators for other markets, other entrepreneurs that are looking at spaces like California and Canada, how that impacts, so we’re really excited to kind of talk about what we’re seeing here and see what kind of insights we can derive.

Noel Abbott:    Awesome. So, yeah, now we’re almost four years into having a legal market in Washington, and I think it’s been about two years since the medical industry was kind of shut down by the legislature. Since then, a lot of startups have tried to hit the ground running, but due to the volatility of the market and other unforeseen challenges, many of them have either been forced to shut down or sell their business. Over the past four years, how many producers have ultimately operated in Washington, and how many are currently still operating?

Cy Scott:    Sure. So, the state actually publishes license data, so we get a good sense of kind of the total number of licensee holders since initial launch of the market. It’s over 500 retailers and over a 1,000 producer/processors, closer to 1,400 since the beginning. When we look at the data that we track, we do work with processors, but we also look at what we consider brands, so processors being the product manufacturers, the license holders often will have multiple brands underneath their processing license. So, you know, we track close to 1,000 brands. Actually, you know, when we look at kind of year-over-year growth, it actually dipped about 10% this year, you know, from 990 last year to about 900 brands sold this year. Granted, we’re still in the first half of 2018, so we may see new brands coming to the market and we may end up doing better than last year, but it kind of gives you a sense of the number of brands that have been sold in retailers in 2018, about 900. So, you’re looking at about 1,400 licenses. That’s across producers and processors, so the wholesale kind of growers. Some have producer and processor licenses, but when we look at the brands that consumers are purchasing, about 900 is kind of where we’re at today.

Noel Abbott:    Do you think that’s an indicator that the market’s reaching it’s point of maturation where the ability to support that many brands is being tested?

Cy Scott:    I do think so, and a lot of that is reflected in some of the growth numbers we’re seeing. When we look at 2016 versus 2015, you know, we had over 100% year-over-year growth. When we look at 2017 versus 2016, it’s dipped down to about 33% year-over-year growth, and then when looking year-to-date, we’re just over 10% growth this time last year, so you’re starting to see some maturity of the market. The growth is still great and very strong.

Noel Abbott:    Just slowing down.

Cy Scott:    It’s slowing down, exactly. Exactly. So, I think that there is saturation of brands given that processors are often producing multiple brands, sometimes downmarket, value-priced brands, and there’s upmarket, more premium-priced brands. Everyone’s kind of trying everything, seeing what will stick. I think that now given that there’s been a number of years that some of these brands have been in the market, certain brands are getting sunsetted as they haven’t been performing. You know, there could be a limited retailer appetite given that they have finite shelf space. They can only carry so many brands. And a consumer can only juggle so many brands in their head and remembering who’s who. So when you’re talking about, you know, 900 brands for sale on the market, that’s a large number. I think all those factors could be impacting that. That said, by the end of the year, maybe we break 1,000 and maybe we see some more brand growth, but we don’t really expect it to continue.

Noel Abbott:    At the rate that it’s been?

Cy Scott:    Exactly.

Noel Abbott:    Do you know if there are license holders that have had their licenses from the beginning and have still not put it to use for a brand?

Cy Scott:    That’s a good question. We don’t know that from the data that we see directly, given that our data comes from the retailers, but you know, we have heard of such cases. We’ve also heard of license holders that have transferred licenses, of consolidation, things like that.

Noel Abbott:    That’s one thing that I’ve heard a lot of is while companies may be going under, the company, it doesn’t necessarily die. It just has new owners and gets acquired by another company so that the brand can live on even if the original conception of the business didn’t make it as planned.

Cy Scott:    Exactly. As far as we know in Washington, I think there’s only been one producer/processor license that’s been completely retired and hasn’t been transferred or sold. Yeah, so that’s pretty interesting. I think kind of to that brand point, we’re seeing a lot of these larger brands taking more and more of the market. Some recent numbers, this year we’re seeing the top 10 brands taking 20% of the market, which is pretty interesting, given so many licenses that are out there when you’re looking at just 10 brands taking down 20% of the market and in a market like Washington, which is over $1 billion in sales each year. That’s a big amount of the market.

Noel Abbott:    Yeah. Well, let’s talk about pricing and the behavior of prices as the market has matured. Prices have fluctuated quite a bit since legalization took effect both on the retail and the wholesale side. What was the timeline of the major trends in this regard, and did you notice a consistent correlation between retail and wholesale prices or have you heard that they were related or did they fluctuate independent of each other?

Cy Scott:    Sure. So, you know when the market first launched prices were very high. Supply was very limited, so that’s just kind of the natural byproduct. That’s something that you hear about in markets like California where people are complaining about taxation of the product and the high prices. I mean, it really is just a supply-and-demand problem in the near term. You know, we saw some very significant price decreases in 2016 and 2017 at the retail level. You know, at this point, prices have stabilized quite a bit. That said, we’re looking at it from the retail side of the business and from the processor/distributor/vendor/wholesale to retailer. We have heard of grower prices, price per gram or per pound kind of continuing to decline, but at the retail level prices have stabilized somewhat. Overall, average item price has dipped a bit, but we see more people purchasing more products, so basket size is essentially the same. So, a basket, you can think of like a transaction. Basket has been pretty consistent, you know about $30-32 per transaction.

Noel Abbott:    So people kind of know in their mind potentially, that they’re going in, with this amount of money to spend, that they’re going in with a fixed budget.

Cy Scott:    Exactly.

Noel Abbott:    That behavior hasn’t really changed at all?

Cy Scott:    Exactly. Yeah. They have a planned spend and they’re just purchasing more products at the transaction. We also see, you know, margins, and margins are roughly 50-55% across all the categories that we track. It varies category to category, but that’s kind of a good ballpark. So, you know, pricing is holding, so I think at the retail side, you know, they seem pretty happy with the margins. I mean, those are good margins for retail. You know, the processors are hopefully able to produce the product at the rate that they’re generating some good margins. Again, we don’t really have visibility in the wholesale side of the business, but at the retail side pricing has kind of stabilized and we expect it to kind of stay right where it’s at for the foreseeable future.

Noel Abbott:    Yeah. I’ve definitely heard from a lot of growers that there has been a “race to the bottom” in terms of the wholesale prices and I even saw recently on Facebook someone had said that they noticed an order had been placed for flower at just 20 cents per gram. While you may not have the data to look into those transactions and identify the trends, what do you think might be the main factors to cause prices to drop so steeply, and do you think that this is going to just kind of be the new normal, or is it going to get worse, or is it just a temporary phase that will get sorted out?

Cy Scott:    Yeah. That’s a good question. I think it’s probably a few things. One of them is some of the scale we’re seeing from the larger brands probably putting price pressure on the growers or economies of scale, you know. Maybe it’s 20 cents a gram, but maybe they’re selling quite a bit of bulk product. You know, I think that’s one area. I think there’s probably too much production if we’re talking 20 cents a gram wholesale price. That’s pretty low. You know, while it is becoming a mature market and we’re three years into it, there’s probably still some changes that we can expect to see. Maybe some more consolidation on the growth side. But, yeah, that is a low price and I do think it has to do with you know probably these brands, these processors driving the price down. They’re probably needing to keep their wholesale cost or their supply cost in line so they can get those margins to the retailer so that might be putting pressure on the growers themselves. Hopefully it stabilizes for those growers. Hopefully there continues to be more increase in demand. I’m not sure how many more licenses are going to be issued on that side, but you know, I would think they’d probably want some limitations around that as well to help maintain some of that wholesale pricing.

Noel Abbott:    Have you noticed the volatility and the tumultuous nature of the market affecting different types of producers and different business models differently? For example, are there certain product categories that have proven themselves to be more or less secure than others?

Cy Scott:    Yeah. I think that, you know, we track about nine categories of products right now and that’s everything from flower to pre-roll, concentrates, vapor pens, capsules, tinctures, topicals. It’s a wide variety of products. I think that what we’re seeing is certain categories like flower continuing to lose market share. That said, there’s still well over 50% of sales go to flower product, but flower, it’s an interesting category. That has the largest amount of brands in that category. I think the barrier to entry is the lowest, right, because it’s the product and the curing process and the packaging is relatively simple compared to maybe producing an edible. You know, with an edible you have to have not only the packaging and processing, but some sort of recipe. You know, you need a commercial-grade kitchen facility that’s licensed to be able to produce, so harder to …

Noel Abbott:    Not to mention all of the knowledge and the experience that would be separate than people who have been growing forever may already be familiar with. They’re kind of inventing a whole new commercial operation when you get into the really complex edibles and processed products.

Cy Scott:    Totally. I mean, that’s exactly it. The same thing with things like vapor pens and concentrates. I mean, the extraction process can be complex. There’s a variety of ways of doing it. There’s technology involved. There’s quality control. That’s stuff that you know you don’t get at the same level with flower. That said, you know, flower is very versatile. You know, it’s very popular, arguably a richer experience for many given kind of the nuance of the strain and the flower production, but we are seeing a little more stability in some of the more complex categories like edibles and vapor pens. Not to say that they’re not challenging and there’s not competition. It just doesn’t seem to be at that same rate that you see in flower. So, you know, if we had to pick a category that’s a little more secure it might be one of those that does require some additional knowledge, some additional labor to produce the product versus something like flower.

Noel Abbott:    Do you think that the lower number of brands may also have something to do with the security from a consumer’s perspective to, that it’s easier to develop brand loyalty perhaps?

Cy Scott:    Absolutely. You know, it’s just you recognize a brand and you like the flavor of the edible. Maybe it’s a low-dose mint and you like the taste and the consistency, so you might go with that brand. The flower purchasing process is a little bit different. You kind of walk in. If you have some idea of a strain you might be interested in or even a processor, you might want to know what new strains are available. Often, you know, retailers don’t carry every strain that a processor produces, so you’re always looking for what’s new and maybe you like a particular strain and that brand has run out at the retailer, so you’re looking for a comparable from another brand and it’s easy to kind of jump and you get introduced to a different brand. That can be harder for something like a vapor pen or an edible, beverage, things like that where the replacement is not as simple.

Noel Abbott:    Right.

Cy Scott:    I think that definitely does have an impact on some of that security for sure.

Noel Abbott:    Now that we’re in this phase in the market where there are companies that have kind of been duking it out and fighting for market share for several years, what do the most successful companies that have been operating since the early days seem to have in common with each other?

Cy Scott:    Sure. So, I think when we look at those large brands that are very successful there’s a couple common factors, one of which is distribution, so having a broad reach. You know, since we’re talking about the Washington market, Washington State, those that aren’t’ familiar, kind of has a western part of the state and an eastern part of the state and so it’s the operators that kind of cross both parts of the state that have the largest retailer footprint seem to do really well. Also, those larger brands are producing multiple categories of products, sometimes all categories where from flower to pre-roll all the way to edibles and beverages. So, I think having product diversification is critical as well. It also just positions yourself nicely to see if there’s certain trends maybe. It is at low-dose edibles.

Noel Abbott:    It’s easier to make adjustments as you notice changes in the industry.

Cy Scott:    Exactly. If you’re strictly a flower producer and while flowers command such a large majority of the market the growth rates aren’t there and you see growth in vapor pens or we see 30% year-to-date year-over-year growth and you want to also make a vapor pen, that can be tough to do if you’re not already invested in that. So, that is one of the trends, is just continuing to invest in your product, product selection, product catalog, what you’re producing, what you’re giving customers. I think customers, as they start to gravitate towards these brands, you know, we’re still kind of early for brand loyalty, but as you do start to identify with maybe a certain brand, if you know that they’re producing other categories of products then you’re going to continue to purchase from that brand versus, you know, going to a competitive brand because it’s a different category of products.

We see trends in transaction data where certain categories like beverages are often purchased alongside another category. So, people, when they go to a store aren’t necessarily always just purchasing a basketful of beverages. They’re usually a throw-in item, not necessarily that store driver that gets you there or flower is a little different. You know, flower is something that people, when they purchase flower, often they’re only purchasing flower. So, if you know that beverages go well with other products and you maybe sell one of those other products, it’s great to look at making a beverage, right maybe something complimentary. That’s some common trends. I think customer education, so the brands that are really investing in marketing, albeit marketing can be difficult in this industry, but trying to educate the consumer about the nuances of their product, the benefits of their product, I think that’s helpful. I think some of the larger brands you see, you know, nice packaging. You know, good branding really stands out on the shelf space there at the retailer, which is critical, and arguably a way to market given that we can’t do television advertising or even digital advertising on things like Facebook or Instagram is very difficult.

Noel Abbott:    Right. People are having their social media accounts shut down left and right.

Cy Scott:    Constantly.

Noel Abbott:    Even when they say, this is not for sales. They’re just photos.

Cy Scott:    Exactly. So, having great packaging is important from a marketing perspective, and that is another kind of trend that we see with some of the larger brands in the market.

Noel Abbott:    I’ll admit, you know, I like to think that I purchase based on examining the product itself, but it’s so difficult in Washington because you can’t actually take it out and look at it and smell it, so I’ve definitely been convinced by packaging. Just like: “Oh, this looks new. That looks different. I’ll give that a try.”

Cy Scott:    Totally. Totally. Packaging. Budtender recommendation, what they’re hearing is always another driver. You know, so if the brands are working with the budtenders, you know, helping educate the budtenders, doing outreach I think is pretty important because they do kind of maintain that relationship with the consumer when they come in. So, those are just some parallels that we see for sure across these larger brands.

Noel Abbott:    Yeah. A lot of producer/processors in Washington have told me how difficult it is to actually get your products into the retailer shops because they’re being solicited nonstop, retailers and bud tenders. They have all of these different brands trying to give them samples, trying to push their product to get that shelf space, and it’s really hard to break through the noise. Even if you have unique selling points it doesn’t really matter. There’s just such a saturation that everybody’s really wary of being pitched and nobody wants to commit to anything. With that in mind, what are some things that you think producers can do to kind of gain an advantage and really help their brand be the one that gets through to the retailers and the bud tenders and is the one that, you know, sticks with them?

Cy Scott:    Yeah. That’s a great point. It can be difficult. You know, when you think about a retailer, you know, they have finite shelf space, right. They only have so much real estate, so much room in the display cases or on the wall behind them. You know, we help retailers through the business intelligence side of what Headset does to really help them optimize their inventory, optimize, you know, the products they carry so that they can better determine when products maybe should be sunsetted or they should discontinue certain brands over others. Hopefully, that starts to generate opportunities for some of these new product manufacturers that are coming to the stores. But, you’re right, it can be a hard selling point, right, especially if you’re producing flower and it’s a Sativa strain and maybe it’s a strain that they already sell from another vendor. It can be difficult to kind of crack that retailer to get into that store. So, you know, we think that there’s things you can do as a product manufacturer that will help. Obviously, you need to have great product and consistent supply, you know, good price point, but if you can provide a little more value to the retailer I think there’s a lot there as well.

One of the services that we have at Headset we call Headset Bridge, which essentially is a vendor-managed inventory platform. We have a lot of retailers that leverage that system and work with product companies to be able to share data back to those vendors specifically, their inventory, their price point, their sales velocity and the vendors, the product manufacturer uses that information to better support the retailer. As you can imagine, a retailer is very busy. You know, a lot of them have a lot going on. They’ve got inventory managers sometimes. Sometimes the inventory manager is the store owner, you know, juggling a lot of things. So, if you can go into a story and say, not only will I give you consistent product that’s well regarded, but I can also provide additional services and make sure that you never run out of stock because I can do vendor-managed inventory and make sure that you’re always well supplied with that Goldilocks amount of inventory, you know, not too much, not too little. You know, that’s valuable for them. Maybe you want to run a promotion and you can cross promote that retail location.

Headset Bridge allows you as a vendor to measure the impact of that promotion and to really show ROI to the retailer to say, look, this is my advertising spend and this is what I’m doing out there, and this is how much it drove sales at your store.

Noel Abbott:    Not only are you doing these kind of co-marketing efforts, but you’re also able to demonstrate that they’re having an effect.

Cy Scott:    Exactly. Again, it comes back to just the retailers being very busy, right. If they do determine, I’ll carry some of your products to see how it does, you can show, you know, right away, kind of ROI there. So, I think coming to a retailer with a great product, but also some value-add services goes a long way to making sure that you can keep that shelf space or get that shelf space in the first place.

Noel Abbott:    Awesome. So, looking ahead at some of the new markets that are coming online, obviously California is going to be huge. Canada is going to be huge. I think they’re actually about the same population wise, about 40 million people, compared to Washington and Colorado, which are, you know, 4 to 5 million. How do you anticipate the growth in these new markets will differ from Washington’s growth and how will the differences in the regulatory structures affect this?

Cy Scott:    Sure. Yeah. That kind of goes back to the topic that what’s exciting about a market like Washington or a market like Colorado is it’s a good lens into the kind of future into a market like California or Canada. Given California has had a market for a long time, you know, from the medical world, but you know, this is the first time that they’re able to sell adult use, you know, 21 and over without a doctor’s recommendation. So, you’re going to see some changes. I think that you’ll probably see a lot of patterns.

The product category sales like we see now where things like flower in the beginning of a market drive a huge percentage, 90% of sales. In a market like Canada, right, where they’re going to go online this year selling only flower and tinctures, obviously given that it’s really pretty much only flower, most of the sales are only going to go to flower, but as they start to introduce some new product categories based on upcoming legislation, so being able to sell edibles and vapor pens you’re going to see kind of a shake-out where flower is, you know, 50% of the market, edibles 10% of the market, concentrates about 10% of the market and so on. So, you’ll start to see some of those same patterns happening. You know, California already somewhat has that. You know, they’re converting a lot of the medical products now. There’s that six-month grace period where they’re able to sell. We’re still within that in the first half of 2018. You know, that will probably change once all the licensing structure is finalized and licenses have been issued at which point you’re probably going to see numbers more in line with what you see in Washington and Colorado around percentage of market going to certain categories.

We’re probably going to see the same pattern with a number of larger brands taking a large percentage of the market. You know, if you can think about, like you said, the population differences, I mean, six, seven times the population, six, seven times probably market size, so you’re looking at $6, 7, 8 billion dollars a year in sales for California and the same thing for Canada. If 20% of that market is going to 10 brands, that’s a sizable amount. And those 10 brands that I mentioned earlier are not all created equal. It’s not divided up equally, so there’s some big winners in that. So, expect to see that as well. It’s to be determined who those brands are going to be. In a market like California you have some legacy medical brands that had good reach, had good dispensary footprint and continue to have that, although I think they’re going through …

Noel Abbott:    They have a consumer following as well.

Cy Scott:    Exactly. Consumer following from the medical days, so that will carry some significant weight going forward, so we can expect them to continue to be leaders. But, in a market like Canada where there are like LPs, licensed producers that are in the medical market.

Noel Abbott:    It’s a lot more strict in terms of who they’re issuing these licenses to and there’s a lot fewer of them going out, right?

Cy Scott:    Exactly, and their audience, I think the Canada medical patient count is roughly 250,000 patients for the entire country. You know, they’re kind of starting over in a lot of ways, probably not a lot of consumer sentiment or people that know those brands immediately like maybe in California where they might. So, that’s going to be quite interesting to see how that shakes out. California has an interesting model with distribution and Canada as well, so that will be interesting to see how that impacts these brands and these product manufacturers. In markets like Washington and Colorado a lot of the distribution is done directly by the processors themselves. So, as they go to a more traditional distribution model, it will be interesting to see how that helps or hurts potentially the processors given that they might not have that direct relationship with the retailer. That relationship may exist through the distributor. You know, that could be interesting, but it also provides benefits because the product manufacturer can focus on manufacturing products, not logistics in distribution. So, that will be a interesting dynamic to see how that changes the landscape versus a market like Washington and Colorado.

Noel Abbott:    I wonder how much leverage the distributors are going to have over which brands get placement on the retail side of things as well.

Cy Scott:    Exactly.

Noel Abbott:    It’s kind of like in Washington producers are almost responsible for their own placement to a degree. You know, they’re the ones out there selling their products to the retailers, but then in California they may have to hand that responsibility over, which might be a scary thing to do.

Cy Scott:    Yeah. Exactly, especially given the limited marketing abilities a lot of these processors have. They leverage the in-store displays and positioning to really be that marketing channel for them. It will be interesting to see how that plays out. We’ve seen things in Canada. There’s a lot of press coming out of Canada given some of these LPs are publicly traded. You see a lot of press releases and news about deals that LPs are making with retail outlets, investments they’re making in retail outlets to try and build that relationship because I think that they’re aware that the distributor will own it in a lot of ways, so they’re trying to create relationships to continue that. But, that’s something that we’re excited to see how that will play out. Another nuance of those markets that will be interesting in California and Oregon, you have the delivery model, which has existed for medical, but to see what that looks like in an adult-use market is new and something that Washington and Colorado do not have. And then to that point, in Canada there’s going to be eCommerce in many provinces, not all provinces I believe. Some provinces will be government-run eCom. Others will be private. Some will be a hybrid.

Noel Abbott:    Is that where you place the order online and it gets shipped to your house or would you go pick it up at a pharmacy?

Cy Scott:    It gets shipped to your house.

Noel Abbott:    Okay.

Cy Scott:    Given that Canada will have federal legalization this year, they can do more traditional eCommerce, so the Amazons of the world could technically sell Cannabis. Well, maybe not technically. Maybe they’d have to have a license to do it, but similar situations where you go online and you go to a website. You add things to your cart, you check out and it’s delivered much like you can purchase alcohol online in the US. That will be an exciting dynamic. And then we’re really looking forward to seeing what kind of brands come out of these new markets. You know, we see news in Canada of LPs building out their adult-use brands. Kind of, they’re already starting to get ahead of it. Given that it’s going to be just flower and their tinctures that they’re able to sell now, it will be interesting to see what happens to that market as the legislation loosens up a bit. You might have seen some of the news about the packaging restrictions. It’s all plain-color packaging, small logo, which is very different than what we’re talking about in Washington where packaging is a different way for brands to stand out. So, a lot of exciting stuff ahead and we look forward to working with retailers in these markets to be able to see what’s really going on.

Noel Abbott:    Yeah. Another thing I could see being very different in the upcoming California market is just the allowance of investments. I know in Washington it was pretty strict when the market launched. You had to be a resident for so many years and they weren’t just allowing anybody to come in and invest in the industry, but I think in California it’s wide open and the legacy growers and people who’ve been operating in the industry for a long time are just going to be flooded with all these new, competitive, well-backed companies. It’s definitely going to be a difficult time and a very competitive market for sure.

Cy Scott:    It is. It is. Yeah. It’s definitely a double-edged sword, you know. You want more capital coming into the space. I’m sure those legacy growers that have been doing it for a long time, they’ve been starved for investment.

Noel Abbott:    Yeah. They’re going to be able to take that investment money.

Cy Scott:    Exactly. Exactly. It’s kind of making sure that they can get that investment money and put it to good use to maintain their positions and scale their businesses and then on the flip side of that the new people coming into the space that might not have the experience in the cannabis industry, you know, they need to be able to take that capital and make smart decisions with it because, you know, cannabis, while it is, as we see in mature markets like Washington, playing out very much like other consumer packaged goods, it does have its nuances, right. It’s a very unique product and I know we create parallels to things like alcohol in a lot of ways, but it’s more than just alcohol, right, when you’re talking about things like topicals, you know. It kind of like, just in that example, starts to push into like skin care.

Noel Abbott:    Right. It’s not just a recreational substance in a lot of ways. It’s a therapeutic substance. People use it for all kinds of things.

Cy Scott:    Exactly. So, coming to the industry from one lens, one framework, it’s more nuanced, so the people that will be coming in now that investment is allowed in markets like California, hopefully they can identify that and stay competitive. On the other side, the ones that have been in the business for a long time are able to scale their operations in this kind of new world that we’re all operating in.

Noel Abbott:    If I’m a producer startup in one of these new markets such as California, what things should I watch out for in terms of industry trends and what should I beware of in terms of the direction that the market’s heading and how that can affect my business and are there steps that I could take to kind of mitigate the risks associated with that?

Cy Scott:    Sure. Yeah. So, we definitely recommend everyone utilizing data to drive their decisions. You know, it used to be okay long ago to just say, I’m going to make an edible and I’m going to package it like this and it’s going to sell well. That’s definitely not the case now. So, you know, definitely looking at the data and as far as what data to look at, I think it’s great to start at a high level at the category or segment level, right, so really determine are you going to be producing a vapor pen or should you focus on a pre-roll, and if it is a pre-roll should you be looking at connoisseur pre-rolls versus multi packs or single-gram pre-rolls and then once you kind of determine where the opportunity is by looking at not only the market share, but the growth rates of those categories, I would start to look at the competitive landscape and find other operators there. Who’s going to be the competition? Who’s there now that’s producing in that subcategory that you’re looking at? What products are they selling that are doing well? Why are those doing well? What do their margins look like? Then start to look at things like price elasticity and finding out, you know, where can you price your products that fit the market.

If you’re new to the market maybe you compete on price. Maybe you’re a higher price because it’s a more premium product. I think looking at those numbers is a really good starting point to building that brand. So, I would start at kind of the category market share. You know, look at percentages. Look at the number of operators that are in there. Look at where the majority of the sales are going. Look at new product introductions. We’ve got great dashboards for that where a new product comes to market. We highlight it. We talk about how well it’s doing immediately so you can kind of start to dig into that and see kind of if it’s something maybe noisier than other categories. Maybe jump to those categories. There’s a lot of categories like the capsules, the tinctures and topicals that have very high growth rates, but have very small market share right now, you know, 1-2% of the market. You know, maybe that’s where you want to be. Maybe you want to be scale, produce a little bit of everything if you can. It’s a very costly endeavor. It takes a lot of expertise. You know, it’s easier said than done, but I would definitely attempt that because it seems like scale is where you’re going to really win.

Noel Abbott:    You’ll have that ability to make pivots as needed or to identify the areas that are performing best for you.

Cy Scott:    Exactly. And then from there I would look at services, value-add that you can provide, and not just the product you produce, but also the services that you’re able to provide your retail customers as a big differentiator as you go to market.

Noel Abbott:    Well, Cy. Thanks for having me. Unfortunately, that’s all the time we have for today. Thanks again for the opportunity to come down here and record the show and for sharing your insight on the growth and the maturation of the Washington market and what we can expect in the emerging markets.

Cy Scott:    Yeah, thanks. Pleasure to be here.

Noel Abbott:    This has been a special edition of the Ganjapreneur.com podcast. You can find our podcast on our website Ganjapreneur.com as well as iTunes, SoundCloud, or wherever you download podcasts. I’m Noel Abbott. Thank you for joining us.

 

End


Ohio MMJ Market Delayed, Sales Won’t Launch on Sept. 8

Cannabis patients in Ohio won’t have access to medicine by the September 8 deadline for launching the program due to delays in the licensing process for the state’s 25 growers, according to a Cincinnatti.com report.

While licenses have been issued, cultivators can’t actually start growing until they have passed inspections with the Ohio Department of Commerce. As of this week, just one grower — Pure Ohio Wellness — has undergone inspection, but was not certified to begin operations. According to a Commerce Department spokesperson, two smaller growers have scheduled inspections for later this month and five large operators will receive inspections in July.

“We really should have had plants in the ground by this time.” — Mark Hamlin, Ohio Commerce Department spokesman, via Cincinnatti.com

Assuming the upcoming inspections result in at least some cultivators being certified to begin the growing process, it will be another three months at least before those cannabis products begin hitting dispensary shelves.

Charlie Batchell, whose company Cresco Labs is constructing a grow facility in Yellow Springs, emphasized that Ohio isn’t the first state to face delays in the roll-out of its medical cannabis program.

“It’s more important for a state to get this right than to try to hit deadlines that might have looked good on paper. …Delays are going to be measured in a matter of days and weeks – not months.” — Charlie Batchell, CEO of Cresco Labs, via Cincinnatti.com

End


Sheets of $100 dollar bills lying flat on a surface.

MedMen to Buy Florida Cannabis Operator for $53M

California-based MedMen intends to buy a Florida medical cannabis operation from Treadwell Nursery in a deal worth $53 million, according to the Sun Sentinel.

Treadwell, who operates in the cannabis space under the name “Remeny Wellness,” will be transferring its five-acre cultivation site in Eustis and the company’s right to operate up to 25 dispensary locations. MedMen will pay half of the agreed $53 million in cash and the other half in company stock traded on the Canadian Securities Exchange, where MedMen was recently listed.

“For nearly a decade we have been positioning ourselves to capitalize on enormous market opportunities like this. This acquisition is right in line with our strategy of establishing a presence early on in high potential markets with limited licenses and large populations. — MedMen co-founder and CEO Adam Bierman, in a release

Why Florida? Florida is the third-most populous state in the U.S. and its medical cannabis marketplace could reach as high as $1 billion in annual sales by 2020.

“[The deal] reflects the belief nationally and internationally that Florida is a very strong medical cannabis market, even though it is in its infant stages.” — Jeff Sharkey, founder of the Medical Marijuana Business Association of Florida, to The News Service of Florida

MedMen currently operates 18 facilities in three of the largest and most robust state marketplaces: California, Nevada, and New York. According to the report, MedMen’s deal with Treadwell should close within 90 days but is “subject to customary closing conditions, including receipt of state regulatory approvals.”

End


Steep Hill Offers Compliance Consulting as California Approaches July 1 Regulatory Launch

California’s adult-use cannabis marketplace opened for business in January, and although regulatory compliance has been mandatory for cannabis goods produced in 2018, many have avoided state-mandated testing. The second phase of regulations come into effect July 1, and cannabis companies in California are expected to be 100 percent compliant with all state and local laws.

In preparation for the implementation of more rules, cannabis testing laboratory Steep Hill is offering compliance consulting services to help their industry partners get compliant, put proper standard operating procedures in place, and successfully plan their business’ growth in the industry’s new regulatory framework.

Director of Cultivation Science Lydia Abernethy said, “Many operators in California’s cannabis industry are unaware of looming regulation updates. This is a time of great change as folks enter the world of compliance and safety testing.”

Enter Steep Hill. Through the company’s Cultivation Science program, Steep Hill is well-practiced in working alongside cannabis startups, whether a large-scale producer or a small, cottage business. Their experts assist growers with pest management, establishing procedures to keep operations compliant and smoothly running, and more in-depth consultation services to troubleshoot manufacturing problems or develop more robust cannabis products. These services are strategically geared towards producing safe, compliant goods for patients and consumers while alleviating stress for producers.

“Product recalls are expensive and regulatory failure can jeopardize a business’ license. It’s best to avoid unnecessary problems by incorporating sound practices at the start,” said Abernethy. “It benefits everyone when the industry complies with regulations. It is our collective goal to provide safe, effective medicine to patients and adult users.”

Steep Hill’s compliance consulting is also available for domestic and international cannabis entrepreneurs, with a honed focus on locations with satellite labs such as Washington, Oregon, and New Mexico, where their experts can help get you and your business up to top speed in this fast-moving industry.

California’s regulations are kicking off in just a few short weeks, so don’t wait — visit SteepHill.com or email info@steephill.com to learn more.

End


Florida Judge Upholds MMJ Decision, Says Smoking Ban is Unconstitutional

Leon County Circuit Court Judge Karen Gievers on Tuesday upheld her May 25 ruling, lifting a stay on her decision that the Florida legislature’s statewide ban on smokeable medical cannabis products is unconstitutional, the Tampa Bay Times reports.

Judge Gievers said that the state has until June 11 to enact a process to allow smokeable cannabis products on the market.

According to Judge Gievers, who is no stranger to standing up for the medical cannabis community, the state’s attempt to stifle the industry has led to irreparable harm to patients.

“First, they cannot legally access the treatment recommended for them. Second, they face potential criminal prosecution for possession and use of the medicinal substance.” — Judge Gievers, in her ruling

In April, Judge Gievers ruled in favor of a stage 4 lung cancer survivor who was suing to grow and juice his own cannabis plants.

Florida‘s medical cannabis law was approved in 2016 by a 71 percent supermajority of voters. As written, the law should have operated as a fairly average, comprehensive medical cannabis program — but lawmakers stepped in to block some of the program’s basic functions, including smokeable products and the right for patients to grow their own medicine.

The Florida Department of Health, which has appealed both of Judge Gievers’ recent pro-MMJ rulings, would not disclose whether or not it would move to allow smokeable products.

“The use of medical marijuana is outlined in state law, which was passed by an overwhelmingly bipartisan majority of the Florida legislature. Our focus remains with ensuring that patients have access to medical marijuana, and the Florida Department of Health has made significant progress in making this treatment available. In fact, there are more than 117,000 patients who have access to medical marijuana and over 1,300 doctors are licensed to order this treatment.” — Devin Galetta, DOH spokesperson, in a statement

End


The U.S. Capitol Building, located on Capitol Hill in Washington D.C.

U.S. Senate Unanimous In Support of Industrial Hemp

The U.S. Senate on Tuesday unanimously and without amendment passed a resolution recognizing the economic potential of industrial hemp. The non-binding measure was passed in recognition of Hemp History Week, according to reporter Tom Angell’s investigation for Forbes.

This is the third year in a row that the U.S. Senate has adopted non-binding resolutions recognizing the value of hemp, though Congress has yet to fully legalize industrial hemp production.

According to the resolution, the global hemp market is estimated to consist of more than 25,000 products. The value of hemp products imported into the U.S. solely for manufacturing is estimated at $76 million. Hemp retail sales in the U.S. are estimated to be over $570 million. The resolution also states that the U.S. is the largest consumer of hemp products in the world and the only major industrialized country that restricts its farming.

Tuesday’s resolution was cosponsored by Sen. Mitch McConnell, who introduced a separate bill this session that would legalize industrial hemp nationwide. The past three years of vocal but non-binding support for industrial hemp from the Senate indicate the bill may have a good chance to pass. Already, nearly a third of the Senate has signed on to cosponsor the bill.

While Sen. McConnell has emerged as a staunch supporter of industrial hemp, he has been clear that he does not support legalizing cannabis.

“Since Kentucky’s earliest days, industrial hemp has played a foundational role in our agricultural history and economy. With our Hemp Farming Act of 2018, I believe that hemp can also be an important part of our future. Removing hemp from the federal list of controlled substances will give our farm communities the opportunity to explore the potential of this versatile crop. I am proud to join with farmers, processors and manufacturers across Kentucky to celebrate Hemp History Week as we work together on the plant’s growing future.” — Sen. Mitch McConnell, in Angell’s Forbes report

End


The purples and greens of an indoor, professional cannabis grow operation.

Michigan Legislature Misses Deadline to Act on Cannabis Legalization

The Michigan Legislature has decided to pass on Tuesday, June 5th’s midnight deadline to act on a voter initiative to legalize adult-use cannabis, the Detroit Free Press reports. Senate Republicans had wanted to take up and pass the measure before it was put on November’s ballot in order to immediately amend the language of the initiative but were unable due to insufficient support in the House of Representatives.

The initiative will now appear on the Nov. 6 general election ballot, to be decided by voters.

Michigan Republicans had sufficient state Senate support to act but were short of the 55 votes needed to pass in the House.

“There’s simply not support in the chamber to pass this right now. The voters are going to have to decide. We’re nowhere in the ballpark.” — Speaker of the House Tom Leonard, via Detroit Free Press

Lawmakers had three options to deal with the initiative: pass the proposal to amend it later, come up with their own competing proposal for the ballot, or do nothing and let the measure go to the general election ballot to be decided by voters. They opted to do nothing. If the measure is approved by voters in November, it will take a three-quarters super-majority vote in the legislature to amend the proposal. Modifying the proposal with just a simple majority would have only been possible if the legislature had acted by Tuesday’s deadline.

Republicans in the state Senate wanted to keep the proposal off the ballot because it’s expected to drive more voters to the polls. Higher turnout has historically helped Democrats, which may jeopardize the Republican majority that exists across the legislature, governor’s office, and in the federal Congress.

Josh Hovey, a spokesperson for The Coalition to Regulate Marijuana Like Alcohol, was satisfied with the outcome.

“We are confident Michigan voters understand that marijuana prohibition has been an absolute disaster and that they will agree that taxing and regulating marijuana is a far better solution. Multiple polls show that roughly 60 percent of Michigan voters want to see marijuana legalized and regulated.” — Josh Hovey via Detroit Free Press

The ballot proposal, as it stands now, would:

  • Legalize the possession and sale of up to 2.5 ounces of cannabis for personal recreational use for people over 21, with up to 10 ounces stored in the home.
  • Allow communities to decide whether they’ll allow cannabis businesses in their towns
  • Tax cannabis sales with a 10 percent excise tax at retail as well as 6 percent sales tax.
  • Tax revenues would be divided, with 35 percent going to K-12 education, 35 percent to roads, and 15 percent each to both the counties and communities where cannabis businesses operate.
  • Require testing and safe transportation of cannabis

End


Colorado Gov. Vetoes Bill Making Autism a Qualifying Condition for MMJ

Gov. John Hickenlooper, in a record-setting ninth veto of the year, rejected a bill that would have added Autism Spectrum Disorder to the list of conditions qualifying for medical marijuana on Tuesday, the Denver Post reports.

Hickenlooper said, regarding the veto, he could not ignore overwhelming concerns from the medical community.

“If we sign that bill we end up, without question, in some way encouraging more young people to look at this as an antidote for their problems.” — John Hickenlooper via The Denver Post

State lawmakers cannot override Hickenlooper’s veto because the legislative session has ended. The governor’s office said Hickenlooper met with families of children with autism while deciding whether or not to veto House Bill 1263. Several mothers and their children camped outside the governor’s office as they awaited news of the decision.

Sen. Steve Fenberg of Boulder was one of the bill’s primary sponsors. He rejected the idea that allowing medical marijuana use for autism would have led to more children without the disorder consuming cannabis.

“I think its unfortunate. I think there are a lot of families that it would benefit. The reality is the traditional pharmaceuticals aren’t always the right choice for these kids, either. This is not for people who have just a little bit of Asperger (syndrome) or something. This is for people who have kids who at the end of the day are hurting themselves. It’s not a justification to be able to smoke pot. It’s genuinely about medicine to help people. And there’s science behind it.” — Sen. Steve Fenberg via the Denver Post

Gov. Hickenlooper, as part of the veto, ordered state health officials to study whether medical marijuana could be an effective and safe treatment for autism.

End


Colorado Governor Vetoes Cannabis “Tasting Room” Bill

Colorado Gov. John Hickenlooper vetoed a bill on Monday that would have allowed licensed cannabis tasting rooms, citing health and safety concerns, according to a Denver Post report.

The legislation — the first of its kind in the nation — would have allowed adults at recreational cannabis retailers to consume small amounts of cannabis via either a vaporizer or edibles.

Colorado is currently home to several unlicensed cannabis clubs and the city of Denver has also begun issuing licenses for social-use establishments after a successful voter initiative. The vetoed bill, however, would have been limited to recreational stores and would not have allowed consumption of shared or personal cannabis, only cannabis supplied by the establishment.

Hickenlooper wrote in a letter announcing the veto:

“We are concerned that marijuana use at consumption establishments could result in additional impaired or intoxicated drivers on our roadways. …This bill also poses public health risks. Allowing vaporization of marijuana in confined spaces poses a significant health risk for employees and patrons of consumption establishments.” — John Hickenlooper, via The Denver Post

The state legislature cannot override the veto because the legislative session ended May 9. The bill was also opposed by the American Lung Association and the American Cancer Society Cancer Action Network, alongside Hickenlooper.

The cannabis industry has come out strongly against the veto. Chris Woods, owner of the recreational chain Terrapin Care Station, issued a statement:

“What we were trying to do with House Bill 1258 was offer certainty on the issue of public cannabis consumption so that regulators could have a bright line when it comes to enforcement. …In its wisdom, the Colorado Legislature sought to close a significant gap in regulation. It’s unfortunate that the governor chose not to offer another regulatory tool to state and local regulators. This fight is not over.” — Chris Woods, via The Denver Post

End


A cannabis worker scoops up two handfuls of trimmed cannabis product.

North Carolina Bill Seeks to Legalize Possessing Up to Four Ounces of Cannabis

According to a report by the Winston-Salem Journal, a Forsyth County, North Carolina legislator has sponsored a state Senate bill that would legalize the possession of up to four ounces of cannabis flower or plant material (for personal use) before one could be charged with a Class 1 misdemeanor. The language of the bill redefines less than four ounces of cannabis as explicitly not a controlled substance.

The bill also includes the possibility of submitting a petition to the Superior Court to potentially expunge previous possession convictions that would no longer be considered illegal under the proposed law. The sponsor of the bill, Sen. Paul Lowe (D-Forsyth) said he introduced the bill in an effort to decriminalize the possession of small amounts of cannabis.

Currently, possessing a half-ounce or less of cannabis is a Class 3 misdemeanor, punishable by up to 20 days in jail. The highest class of misdemeanor, Class 1, is punishable by up to 120 days in jail. Under current laws, possession of one and a half ounces or more of cannabis is a Class 1 felony, punishable by up to five months in jail. The proposed bill would raise the lower limit for a class 1 felony to one pound of cannabis or more before being charged with a Class 1 felony.

The district attorney for Forsyth County, Jim O’Neill, takes issue with the amounts set by the new bill. O’Neill said he considers Lowe a respected friend but that four ounces of cannabis as an amount for personal use is absurd. It is unlikely the bill will make it out of committee. The North Carolina General Assembly is Republican controlled and currently focused on passing a non-amended state budget by the end of the session, expected the July 4th weekend. Medical marijuana bills introduced in April 2017 also did not leave committee.

North Carolina is one of 20 states without medical or recreational cannabis laws.

End


Report: Canadians to Spend $7B on Cannabis by 2019, Consumption Rates Expected to Rise

Canadians are expected to increase their consumption of cannabis by up to 35 percent and spend as much as $7 billion on cannabis by 2019, according to predictions by accounting firm Deloitte.

The firm’s report takes an in-depth look at the future Canadian cannabis market, surveying 1,500 different adults living in the country between March 6 and March 20. These are just some of the report’s other conclusions:

  • Canadians who already consume cannabis are expected to buy about two-thirds of their products from legal retailers.
  • Consumers in the upcoming market will be most likely younger (aged 18-34) and “more likely to put their health or safety at risk.”
  • Consumers will make purchases more often and will be willing to spend more when doing so.
  • Shoppers in the cannabis industry will prefer visiting brick-and-mortar store locations over placing orders online.
  • Alcohol revenues are expected to take a hit after cannabis legalization, even with many provincial liquor boards playing big roles in the legal market’s rollout.

Canada‘s leaders have talked for more than a year about how to implement this marketplace, but the Senate is expected to finally vote on the Cannabis Act on Thursday, June 7. Assuming all goes well, it could then be several more months before stores actually open.

“It could be the last week of August — it could be the beginning or mid-September. From where I sit, and I’m the sponsor of the bill, if it takes until the first week of October to get it all right, then we should take until the first week of October.” — Ontario independent Senator Tony Dean, sponsor of Bill C-45, to the Toronto Sun

 

End


InstantGMP, Inc. Announces Annual Greenfield Grant for Cannabis and Hemp Processors

InstantGMP, Inc. and their partners are excited to announce the annual Greenfield Grant designed to take Cannabis processors, CBD and Hemp manufacturers from zero to production superstars for brands within investor portfolios. The Grand Prize winner will receive a comprehensive system that will instantly establish their Good Manufacturing Practices.

Fulfilling a Brand’s Vision

Starting a processing or manufacturing operation from square one is a tremendous undertaking especially in an up and coming industry filled with fierce competition under the watchful eye of regulators. It’s critical to hit the ground running with a solid quality system and batch management software.

Now more than ever, companies must work past the risks and tasks associated with building their brand empire, to focus on product differentiation; operations expansion; and building consumer trust through high-quality offerings.

Looking Ahead

Creating and implementing a quality and production system takes time, expertise, multiple resources, and plenty of planning for the future. Many entrepreneurs and startups do not fully understand the process nuances involved in reinforcing Good Manufacturing Practices (GMPs) that is a well-known, proven path to producing high-quality products.

InstantGMP, Inc. will award one Grand Prize Winner a fully encompassing manufacturing and quality system in the form of InstantGMP™ software, a full set of Standard Operating Procedures, extensive training, and a complete roll-out with skilled consultants. Altogether, these components provide the foundation for success in manufacturing.

Greenfield Grant Partners

InstantGMP, Inc. has partnered with the American Herbal Products Association (AHPA), the California Cannabis Industry Association (CCIA), and the National Cannabis Industry Association (NCIA) to publicize this incredible opportunity for startups, investors, and investment management companies.

About InstantGMP, Inc.

InstantGMP, Inc. is the creator behind the InstantGMP™ software that organizes and manages manufacturing processes with the goal of improving batch quality and consistency across several different industry verticals; including biopharmaceuticals, biotech, cannabis, CBD & hemp, cosmetics, dietary supplements, e-liquids, and medical devices. The software is the brain-child of Dr. Richard Soltero, pharmaceutical veteran, and quality extraordinaire. InstantGMP, Inc.’s focus is developing software for products that are regulated by the FDA.

About our Partner: American Herbal Products Association

Founded in 1982, the American Herbal Products Association (AHPA) is the national trade association and voice of the herbal products industry. AHPA is comprised of more than 350-member companies, consisting primarily of domestic and foreign companies doing business as growers, processors, manufacturers and marketers of herbs and herbal products as foods, dietary supplements, cosmetics, and non-prescription drugs, and but also includes companies that provide expert services to the herbal trade.

AHPA’s mission is to promote the responsible commerce of herbal products to ensure that consumers continue to enjoy informed access to a wide variety of herbal goods.

End


A freshly trimmed cannabis nug lying on its side on a wooden table.

Preliminary Study Results Show Cannabis Has Potential as IBD Treatment

Medical cannabis has shown promise in the treatment of inflammatory bowel disease (IBD), according to a report by MedPage Today covering new research unveiled at Digestive Disease Week, which is taking place this week in Washington D.C.

Dr. Mark Silverberg, MD, Ph.D. presented his review of using cannabis to treat IBD and reported that “when you have exhausted other treatments, it isn’t unreasonable” to try medical cannabis, but more research is needed to fully understand the plant’s effects on IBD symptoms.

“It is not clear if cannabis can be used to induce remission in IBD. Further research is warranted to determine if cannabis can be used as an adjunctive therapy to treat symptoms such as nausea, pain, and anorexia.” — Mark Silverberg, MD, PhD, of Sinai Health System in Toronto

Preliminary research has also shown that consuming cannabis for 8 weeks can be helpful for patients with ulcerative colitis (UC), a specific type of IBD.

Dr. Timna Naftali, MD, whose team investigated the use of cannabis to treat UC, said that the control participants of her study — who were consuming two .5 gram cannabis joints per day — reported significant improvements in their Disease Activity Index (DAI) over the placebo group.

“It’s not a magic bullet, but it certainly does have an effect, and I think should be explored further.” — Timna Naftali, MD, of Meir General Hospital and Tel Aviv University in Israel

End


The estate of President George Washington, located in Mount Vernon, Virginia.

Industrial Hemp Comes to Mount Vernon, Virginia in Honor of George Washington

An industrial hemp crop has been planted at Mount Vernon, Virginia in what the estate managers call a truer interpretation of the land as it was once run by the nation’s first president. 

According to a report by The Zebra Press, Dean Norton — the director of horticulture for Mount Vernon — recently partnered with Dr. Michael Timko of the University of Virginia’s industrial hemp program to plant hemp seeds across a 1,000 square foot area at the founding father’s historic homestead. 

Historians believe that George Washington strongly favored hemp as an agricultural product, and at one point he is thought to have believed that the plant could overpower tobacco and wheat as the country’s most important cash crop. Though Washington eventually changed his mind, he continued to cultivate hemp at Mount Vernon, which was used to create rope, thread, and canvas that was put to use around the plantation.

“Through this program, we have been able to return a primary crop to Mount Vernon that has not been grown since Washington’s time which is extraordinary. The processing of hemp will help to expand our rich agricultural interpretive program.” — Dean Norton, Mount Vernon’s Director of Horticulture, to The Zebra Press

Norton said that when the crop is harvested, the Mount Vernon hemp plants will be used to provide fiber-making demonstrations in late summer.

Virginia‘s legislature established the state’s industrial hemp program in 2015.

 

End


A close-up shot of a cannabis plant grown under Washington's I-502 market regulations.

Deadline Approaches for Legislative Action on Michigan’s Legalization Ballot Initiative

According to a Michigan Radio report, advocates from the “Coalition to Regulate Marijuana Like Alcohol” say they are watching closely as the deadline approaches for legislative action on the state’s cannabis legalization issue.

Tuesday, June 5th is the deadline for the legislature to decide whether to approve the petition and write it into law or leave the decision to voters in November. Coalition spokesman Josh Hovey said the petition should be enacted as written with no amendments.

Supporters of the petition collected over 300,000 signatures for the ballot initiative. The language of the initiative follows closely the 2016 Medical Marijuana Facilities Licensing Act. Within the existing language, cannabis businesses would need state permits and communities could decide where those businesses were allowed to operate. Public consumption and driving under the influence would both be prohibited.

A poll released by Michigan State University in May showed that 61% of Michigan voters support recreational cannabis. Polling data suggests that the initiative, if sent to voters, would pass easily — however, Michigan Senate Republicans have floated the idea of approving the initiative outright so that the legislature could immediately amend it. The state House’s position is unclear, however.

“Our position on the legislature adopting it is that there’s no reason to delay ending the failure of marijuana prohibition,” — Hovey to Michigan Radio

End


Louisiana Gov. Signs MMJ Expansions Into Law

Louisiana Gov. John Bel Edwards signed a medical cannabis expansion program into law on Saturday that adds to the list of qualifying conditions that qualify a patient for participating in the program, according to a USA Today Network Friday report.

House Bill 579, which contained the expansions, was first proposed by state Rep. Ted James (D-Baton Rouge).

“It’s something I’m very proud of because this is a medicine I believe can improve the lives of so many people who are suffering,” — James to USA Today Network Friday

James’ bill adds Parkinson’s, glaucoma, severe muscle spasms, chronic pain, and post-traumatic stress disorder to Louisiana‘s existing list of 10 qualifying conditions. Supporters argued that the expansions will help veterans suffering from PTSD and will help curb issues with opioid dependency in the state.

Previously this session, Gov. Edwards signed another MMJ expansions bill — House Bill 672, proposed by Rep. Rodney Lyons (D-Harvey) — that added autism to the qualifying conditions list.

The program previously had covered cancer, Crohn’s disease, immunodeficiency, immune deficiency syndrome, wasting syndrome, epilepsy, seizure, spasticity, muscular dystrophy and multiple sclerosis. 

Louisiana’s medical cannabis program was approved by the legislature in 2016 and is expected to open later this summer. The program does not allow for smokeable products and patients will be required to consume cannabis only as a pill or oil.

End


State Legislatures Address Hemp Policies During 2018 Sessions

It’s, so far, been a banner year for hemp policy as Alaska, Kansas, Arizona, and Oklahoma each passed industrial hemp legislation during their respective sessions while two other states – New York and South Carolina – expanded their programs; while one state program, Wisconsin, came online. Illinois, too, is just one Senate concurrence vote away from sending its own hemp legislation to the governor.

New hemp programs

The industrial hemp legislation approved in the four states all implement so-called pilot programs, requiring farmers to register their crops with the state and, in most cases, partner with an institute of higher education for research and development. Each state requires the plants to contain 0.3 percent THC or less and seeds to be approved by respective state agricultural agencies.

It’s unclear the scope of each state’s program as the definitions for “research” vary from program-to-program in states that permit hemp cultivation. Arizona’s law includes “marketing” in its research definition, which means producers will be permitted to sell their products to consumers. Kansas’ and Oklahoma’s pilot programs require producers to partner with institutes of higher education for research. In Kansas, growers can partner with the University of Kansas, Kansas State University, Wichita State University, Pittsburg State University, Fort Hays State University, and Emporia State University. Oklahoma’s law does not specify the appropriate schools; however, at least two schools – Pawnee Nation College and Langton University – already have partnerships in place. The state’s largest agricultural university, Oklahoma State University, will not participate in the inaugural program because, according to officials, the law was passed too late to get seed in the ground.

Bright green leaves on a young, flourishing hemp plant. Photo credit: Philip Steffan

Alaska’s law excludes CBD from the state definition of “hashish oil” and clarifies that adding industrial hemp to food “does not create an adulterated food product,” opening the door for CBD-infused foods and beverages. Oklahoma’s law specifies that even CBD derived from industrial hemp plants will remain defined as “marijuana” and illegal. Neither Arizona’s nor Kansas’ law specifically address the CBD issue. The issue could be clarified when state officials devise the program rules; emails to agriculture officials in both states seeking clarification on this issue were not returned.

Wisconsin’s industrial hemp pilot program also came online this year, allowing the state’s farmers to grow the crop and sell products to consumers. Earlier this month, the state Attorney General’s Office issued a clarification to the Legislature-approved law, indicating that hemp-derived CBD products would be among those allowed to be offered to consumers. Wisconsin’s law could be seen as a breath of fresh air in a state with a CBD-only medical cannabis program.

Hemp program expansions

Two states also announced expansions to their hemp programs: New York and South Carolina. New York Gov. Andrew Cuomo in April announced that hemp would be cultivated on 3,500 acres throughout the state, up from 2,000 in 2017, and that the state would earmark $650,000 for a hemp processing plant, another $2 million for a state-run hemp seed certification program, and another $10 million in grant funding to advance hemp research and economic development opportunities – a considerable investment for a burgeoning industry. Cuomo indicated that more than 60 new farmers and businesses received hemp cultivation permits for this year, in all there are about 100 licensed cultivators in the state, according to a Press Connects report.

In South Carolina, officials have doubled the number of available permits from 20 to 40 and doubled the number of allowed acres from 20 to 40. More than 130 people applied last year to participate in the program. That state law, however, also requires farmers to partner with a university.

Hemp program setbacks

In Indiana, Gov. Eric Holcomb reportedly requested the Legislature change a bill which would have legalized industrial hemp production to a simple feasibility study. Holcomb spokeswoman Stephanie Wilson told the Indy Star that the governor was “not opposed to the idea oof industrialhemp” but wanted to be sure the state was able to properly regulate the industry. That amended bill passed the House in January, and the Senate the following month. That study is expected by the end of the summer.

Indiana does have an industrial hemp pilot program; however, only Purdue University has grown any hemp crops under the regime.

And in Oregon, lawmakers approved a measure to classify hemp seed as agricultural product “for purposes of statutes regulating labeling, testing, certifying or other aspects of seeds.” The bill includes testing requirements and bars unlicensed individuals from producing, processing, or storing homemade industrial hemp extracts, such as CBD.

However, a month later the Oregon Liquor Control Commission temporarily suspended issuing hemp cultivation certificates to Oregon Department of Agriculture-registered growers until the agency completes the rulemaking process.

In all, 39 states now allow some form of hemp production – which remains illegal at the federal level. In April, Senate Majority Leader Mitch McConnell introduced legislation to change that. The Hemp Farming Act of 2018 carries 24 bi-partisan cosponsors.

End


California Senate Advances Bill Establishing Statewide Cannabis Banking Services

The California Senate has advanced Senate Bill 930 — a.k.a. the Cannabis Limited Charter Banking and Credit Union Law — which seeks to establish new rules allowing California banks to serve businesses who are denied banking services due to their involvement in the still federally prohibited cannabis industry.

According to an Associated Press report, the bill passed through California’s Senate with a bipartisan, 29-6 majority.

If signed into law, SB 930 would permit banking institutions regulated by California’s Department of Business Oversight — including both charter banks and credit unions — to provide limited banking services to the currently cash-only industry. Cannabis companies could use those services to pay rent, to pay state and local taxes (but not federal taxes), or to pay other California companies for goods and services related to the cannabis space.

The limited banking services would not allow for any out-of-state payments.

“We’re not using the federal system, we’re not using the federal wire. This is a short-term creative approach to deal with this extraordinary problem.” — Democratic Sen. Bob Hertzberg to the AP

Lawmakers reportedly consider this move to be just a temporary strategy under the assumption that cannabis will someday be legalized at the federal level.

The bill now moves to the California state Assembly for consideration.

California’s adult-use cannabis industry kicked off in January and is expected to grow into a $7 billion marketplace — it is the world’s largest legal cannabis market, by far.

End


Georgia Parents Treating Son’s Epilepsy with Cannabis Lose Custody of Child

Georgia couple Matthew and Suzeanna Brill have been charged with reckless conduct and have lost the custody rights to their 15-year-old son, David, for giving him cannabis as an alternative treatment for the youth’s epileptic seizures, according to a NY Times report.

According to the Brills, once he started using medical cannabis, their son went seizure-free for 71 days — the longest stretch of relief any medication had ever afforded him.

But when someone alerted the Georgia Division of Family and Children Services, officials came on April 20 and drug tested the whole family. Mr. Brill and David tested positive for cannabis, Ms. Brill did not. The parents then admitted to giving cannabis to their son and authorities demanded that they stop.

“We complied, and within 14 hours of complying we were rushing our son to the hospital. And it was one of the most horrific seizures I’ve ever seen.” — Suzeanna Brill to the NY Times

The Brills spent six days in jail, costing Matthew his job and complicating the family’s financial situation. After his seizure, David spent a week in the hospital before he was moved to a group home 60 miles from where his parents live.

“Even with the ramifications with the law, I don’t care. For 71 days he was able to ride a bike, go play, lift weights. We were able to achieve that with David medicated not from Big Pharma, but David medicated with marijuana.” — Matthew Brill to the NY Times

The Brills have set up a crowdfunding campaign to pay for lawyer expenses in the upcoming battle to regain custody of their son, which they say could take a year or more.

Medical cannabis is technically legal in Georgia, but only for a few specific conditions and only in oil form — also, it remains illegal to grow or process cannabis in the state, so there is no legal method of obtaining the medicine.

Federally, cannabis remains a Schedule 1 “drug” with “no medical use.”

End


The Four Pillars of Quality Cannabis Processing

Cannabis extraction has been used as a blanket term for what is best described as cannabis processing. A well-designed cannabis process goes far beyond just extraction, overlapping heavily with cultivation on the front-end and product development on the back-end [1]. With this mindset, four pillars emerge as critical capabilities for developing the ideal cannabis process: Cultivation, Analytics, Extraction, and Biochemistry.

Taken alone, the purpose and value of each pillar are quite clear, but it is only when combined that each pillar can be optimized to provide their full capacities in a well-designed process. Because of this, it is best to define the goals of each pillar alone, and then determine how they can be further augmented.

Cultivation

Cultivation is the soul of any horticultural process, including cannabis production. Whether the goal is to convert flavors, pigments, or bioactive compounds into a usable form, a natural process should only harness what is provided by the raw material, in this case, the cannabis flower. That means cultivation provides a molecular feedstock for our process and, depending on our end goals, there are many requirements we may have in mind. These requirements start as simply as mass yield. Different metrics that can be used here include mass yield per square foot or per light. Taken further, this yield may be expressed based not only on mass, but the cannabinoid content of the plants grown. This could give rise to a metric like CBD or THC yield per square foot and may be more representative of a successful grow. Additionally, as scientists race to learn more about the ways individual cannabinoids and their combinations interact with the human body, cultivators will be more focused on identifying cultivars that provide unique ratios of cannabinoids and other bioactive compounds consistently. Further, research into the synergistic effect of terpenes with cannabinoids suggests that terpene content should be another goal of cultivation [2]. Lastly, and most importantly, it is critical that cultivation provides clean and safe materials downstream. This means cannabis flower free of microbial growth, heavy metals, pesticides, and other contaminants.

Analytics

Analytics provide a feedback loop at every step of cannabis production. Analytics may include Liquid Chromatography methods for cannabinoids [3], [4], [5] or Gas Chromatography methods for terpene content [3]. Analytical methods should be precise, accurate, and specific. Ideally, they can identify the compounds and their concentrations in a cannabis product. Analytics is a pillar of its own due simply to the efforts required to ensure the quality and reliability of results provided as well as ongoing optimization of methods to provide more sensitive and useful results. That said, analytics are only truly harnessed when paired with the other 3 pillars.

Extraction

Extraction is best thought of as the conversion of target molecules in cannabis raw material to a usable form. Which molecules those are is up to the goals of your product. The spectrum runs from an extract containing only a pure, isolated cannabinoid-like CBD, to an extract containing over 100 cannabinoids and terpenes in a predictable ratio. There are nearly limitless approaches to take in terms of equipment and process optimization in this space so it is critical to identify which is the best fit for the end-product [1].

Biochemistry

Biochemistry can be split into two main concepts. Plant biochemistry focuses back towards cultivation and allows a cannabis scientist to understand the complex pathways that give rise to unique ratios of bioactive molecules in the plant. Human biochemistry focuses on how those bioactive molecules interact with the human endocannabinoid system, as well as how different routes of administration may impact the pharmacokinetic delivery of those active molecules.

Figure 1: When harnessed in tandem the pillars of cannabis processing provide platforms of research and investigation that drive the development of world-class products.

Each of the pillars require technical know-how and resources to build, but once established they can be a source of constant innovation. Fig. 1 above shows how thoroughly each of these pillars are connected. At the intersection of each pillar, unique technology platforms exist capable of driving an innovation and discovery cycle towards the development of ideal products.

For example, instead of blindly processing cannabis based on cultivar name, I could apply analytics to determine the terpene and cannabinoid content of the incoming raw materials and form specifications to ensure the ongoing quality and consistency of my products. Also, analytics can provide feedback as I tweak variables in my extraction process resulting in optimized methods. By applying plant biochemistry to my cultivation with the assistance of analytics I could begin hunting for specific phenotypes within cultivars that provide elevated levels of specific cannabinoids like CBGA or THCV. By understanding human biochemistry tied with well-characterized extracts, I can begin harnessing the overwhelmingly complex polypharmacology associated with multidrug, multitarget plant cannabinoid therapies [6]. When these pillars are harnessed effectively, we can fully characterize our unique cannabis raw material with targeted cannabinoid and terpene ratios, optimize an extraction process to ensure no loss of desirable bioactive compounds, compare our extracted product back to its source, and ensure we are delivering a safe, consistent “nature identical” extract for use in products.

With these tools in hand, we can confidently set about the task of processing safe, reliable, and well-characterized cannabis extracts for the development of world-class products.

[1] Sweeney, C. “Goal-Oriented Extraction Processes.” Cannabis Science and Technology, vol 1, 2018, pp 54-57.
[2] Russo, E. B. “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.” British Journal of Pharmacology, vol. 163, no. 7, 2011, pp. 1344–1364.
[3] Giese, Matthew W., et al. “Method for the Analysis of Cannabinoids and Terpenes in Cannabis.” Journal of AOAC International, vol. 98, no. 6, 2015, pp. 1503–1522.
[4] Gul W., et al. “Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography.” Journal of AOAC International, vol. 98, 2015, pp. 1523-1528.
[5] Mudge, E. M., et al. “Leaner and Greener Analysis of Cannabinoids.” Analytical and Bioanalytical Chemistry, vol. 409, 2017, pp. 3153-3163.
[6] Brodie, James S., et al. “Polypharmacology Shakes Hands with Complex Aetiopathology.” Trends in Pharmacological Sciences, vol. 36, no. 12, 2015, pp. 802–821.

End


Beth Stavola: Operating a Multi-State Cannabis Company

Beth Stavola is a serial cannabis industry entrepreneur who owns dispensaries in Arizona and Nevada; she is also the founder and CEO of Stavola Medical Marijuana Holdings and CBD For Life, and is a member of the New Jersey Cannabis Industry Association‘s Board of Trustees.

Beth recently joined our podcast host TG Branfalt to talk about her experience six years ago transitioning from a career in the upper echelons of Wall Street to the “wild west” of the burgeoning cannabis industry. They discuss the differences among state markets, how to work with politicians who still need to learn the benefits of legalization (and the countless drawbacks of prohibition), the ongoing reform progress in Beth’s home state of New Jersey, how she balances the workload of being a mother with six children and multi-state cannabis entrepreneur, and more.

Listen to the interview via the player below, or scroll down for a full transcript of this week’s Ganjapreneur.com podcast episode!


Listen to the podcast:


Read the transcript:

TG Branfalt: Hey there. I’m your host, TG Branfalt, and you’re listening to the Ganjapreneur.com podcast where we try to bring you actionable information and normalize cannabis through the stories of ganjapreneurs, activists, and industry stakeholders. Today I’m joined by Beth Stavola, a cannabis industry entrepreneur who wears a lot of hats, is an owner of multiple dispensaries throughout the U.S., COO and Director of MPX Bioceutical Corporation and a member of the Board of Trustees of the New Jersey Cannabis Industry Association in addition to being a mother of six children. Pretty crazy. How you doing, Beth?

Beth Stavola: I’m doing good, Tim. How are you?

TG Branfalt: I’m all right. Waiting for the thaw here in Vermont, but we’ll get there. Man, I’m having trouble right now.

Beth Stavola: That’s okay. We’re about to get a lot of snow here in New Jersey, too.

TG Branfalt: Let’s hope that we all survive until March, April. Who knows what’s going on. Anyway, I want to talk about you, I want to get to know you, I want to get a bit about your background. How’d you end up in this cannabis space?

Beth Stavola: Well, my background is on Wall Street. I worked, for most of my career, at Jefferies and Company in Institutional Equity Sales. Mostly selling IPOs and secondaries. After children number four and five, twins, I went back to work for about six months. My husband said, “This 7:00 a.m. meeting is probably not working in Manhattan anymore for you.” I started just really doing one-off investments for my family. A deal broker brought me an opportunity to invest $1 million in medical marijuana in Arizona.

I found that it was intriguing and, Tim, better lucky than smart. I’m not going to tell you that I was some incredible visionary. I flew out to Arizona, I came back, and I told my husband I was going to invest $1 million in medical marijuana. He said, “You’ve completely lost your …” Can I say it?

TG Branfalt: Yeah.

Beth Stavola: “You’ve completely lost your shit now.” I bought my first license and it was a pretty crazy story. The first license was on the border of Mexico in Douglas, Arizona. I really planned on investing mostly and not really operating the business. Six and a half years ago, it was the wild, wild west a lot more than it really is now. I ended up having to take over and operate the business. Then I started really enjoying it. I bought two other licenses in Mesa, Arizona. I got super passionate about it. I saw what it was doing to help people and that’s my story.

I remember laying in a bed in a Holiday Inn, staring at the ceiling, and waiting for the Department of Health Services to come down to Douglas, Arizona and give me my first Approval to Operate. I remember just staring at the ceiling all night and saying, “What the hell are you doing?” It’s all worked out. It’s a really exciting business. It’s incredibly challenging with, obviously, the federal illegality. Hopefully, things will be changing there.

TG Branfalt: Can you tell me what the biggest challenge was going from Wall Street to this industry? That’s a night and day sort of jump.

Beth Stavola: You know what? It’s unchartered territory. Because it was in the black market for so long, there’s no playbook and there still is no playbook. When you’re a multi-state operator, like we are, the states change the rules all the time. Sometimes I have to back up and I say, “Okay, which state are talking about now? Is it Maryland, or Arizona, or Massachusetts, or New Jersey?” That’s certainly a challenge.

TG Branfalt: When you were developing the businesses, how’d you end up being so successful? What do you think that you did differently than other people were doing that allowed you to expand and allowed you to get into multiple states?

Beth Stavola: Well, definitely a lot of perseverance. Throwing a lot of stuff against the wall to see what sticks. Learning from my mistakes and the mistakes in this industry are very, very expensive, especially on the cultivation side. Just really taking every meeting. My sister, Julie, works with me amongst a bunch of other fabulous ladies in my office. She would almost make fun of me a little for taking every meeting, but one out of 10 meetings, generally, is going to result in something really great. I really try to leave no stone unturned.

TG Branfalt: You mention your sister. How do you find the right talent? You’re a COO and Director. How do you find the right talent for this space, especially you admittedly didn’t have that experience coming in? Also, what non-cannabis sectors are you finding talent?

Beth Stavola: That’s an interesting question and I talk about it a lot with my counterparts that are multi-state operators. One thing that I joke about is I say it’s like dog years. If you’re in the business six and a half years, it’s like 55 years in any other business. I also joke that I love that sometimes they use five-year-old glamor shots of me because I feel like I’ve aged a lot in the business. It’s really a challenge because the experiences that we’ve had to deal with, whether it’s figuring out what to do with the cash and how to deal with the lack of banking, having your own bank accounts shut down. At a multi-national bank one of my daughter’s communion money accounts shut down because I’m the trustee.

TG Branfalt: Oh, no.

Beth Stavola: Yeah. The banking is one of the most challenging things and that’s one of the things that I really feel like, as a federal government, as one of the things that we have to change quickly, because it really puts people in danger. I sleep with a phone in my bed, certainly, because I have teenagers, right? Also, because I get text messages at night. I know that the stores are closed, all my people have been walked by security to their vehicles, everything has been secured, and that’s really important to me. We’re one of the lucky ones that generally has banking across the board, but it’s a real challenge for the industry.

TG Branfalt: Where are you finding your people? Where are you finding the upper echelon of your executive team and the people who are on the ground in your dispensaries?

Beth Stavola: Former Wall Street, somewhat on the executive team. I feel like if you could survive there, especially during the time period where I was there, you could pretty much wade through anything. My sister, her name is Julie Winters, she was in operations for credit derivative swaps at Barclays. Finding people that come from very highly regulated businesses, gaming, things of that nature.

TG Branfalt: You mentioned the high regulation. How do you decide which markets to enter? Are there specific things that you look for with regard to the states?

Beth Stavola: Yes. We will never be in an unlimited licensing state. You’ll never see us make an acquisition or try to move into, say, a Colorado, an Oregon, a Washington state. Limited licensing states, highly regulated. If it’s a medical state, chronic pain being on the list. It’s generally about 70% of what the medical cards are written. It really depends on how well the state has written the rules. One of the states we’re opening in the next 60 days is Maryland. I’ve been really impressed with Maryland’s program.

TG Branfalt: When it comes to Maryland, I know that there’s a lot going on in terms of the rules being challenged by some minority lawmakers with the social equity rules. Is that something that’s still going on and something that you’re having to deal with?

Beth Stavola: You know what? It is still going on and, frankly, it should be going on, because I’m very, very behind this social justice reform. We cannot be giving these licenses out to only rich, white males when we have men and women of color that are sitting in jail for doing the same exact thing that these licenses are being given out for now.

TG Branfalt: Of the states that you’re operating in, is one more challenging than the other? Do you have a little more trouble in one state versus another? I’m just trying to get a sense of, for multi-state operators, what they might have to deal with if they choose to take that route.

Beth Stavola: Sure. One of the things that I did with the NJCIA is I think the state of Nevada did it right. Now, that said, it is the highest regulated state that we operate in at this very moment. Nevada knows how to do it right, right? They’ve bene regulating highly regulated businesses for years. One of the suggestions that I had for the NJCIA was, you know what? Our new Governor, Phil Murphy, yay Phil, he wants to do so much for this state and changing the medical program here in New Jersey is first and foremost a way that we will head to adult use here, but there’s no state that has switched to adult use better than the state of Nevada.

Senator Tick Segerblom, I’m going to pat him on the back for that. He has done an incredible job pushing that agenda forward there. He and I were able to, along with Dara Servis and Hugh O’Beirne, with the NJCIA, really put together a nice program for state and local officials of New Jersey, to go and see how Nevada did it. They had a really well thought out medical program and, if you think about it, in November of 2016, Massachusetts and Nevada both voted in adult use marijuana. By July 1st of 2017, Nevada had it implemented. That’s an absolute record.

Massachusetts, we’re still waiting for the recreational licenses and we’re looking at about July of 2018. I really wanted some of these lawmakers in New Jersey, as it’s my home state, to see a state that I believe does it right. What we do is we operate all the states to the highest standard of the most regulated state that we operate in, which would be Nevada.

TG Branfalt: I want to talk to you a lot more about New Jersey. I’m on the east coast. I’ve covered New York a whole lot and they’re sort of intertwined; but before we do that, we’ve got to take a break. This is Ganjapreneur.com podcast and TG Branfalt.


If you are looking for a job in the rapidly growing and highly competitive cannabis industry, Ganjapreneur.com is the place to look. Visit the Ganjapreneur Job Board today to browse current openings with cannabis companies throughout the United States. From entry level bud tenders positions to executive level career opportunities. You can also create a profile and upload your resume to be discovered by cannabis recruiters. Visit our Job Board at jobs.Ganjapreneur.com to create your profile today.

If you are a business owner, you can post your job openings for as little as $25 on our Job Board to reach the largest and most engaged audience of cannabis professionals on the web. Companies who are listed in the Ganjapreneur Business Director are eligible for free job listings. If you’re already signed up, contact us today via the website or send us an email at grow@Ganjapreneur.com to activate your unique coupon.


TG Branfalt: Hey, welcome back to the Ganjapreneur.com Podcast. I’m your host, TG Branfalt, here with Beth Stavola, cannabis industry entrepreneur, COO and Director MPX Bioceutical Corporation, member of the Board of Trustees of the New Jersey Cannabis Industry Association. That’s what I want to talk to you about. I want to talk to you about Jersey. You had said before that the first order of business was to strengthen New Jersey’s medical cannabis program. What is happening in New Jersey? You mentioned that Murphy, he’s a proponent of recreational cannabis, there’s bills that have been introduced. What is going on in New Jersey?

Beth Stavola: Right now, Governor Murphy, last week, in his budget speech, he basically is assuming approximately $80 million on revenue coming into the state in 2019, so we really have to get it going. Right now, I believe there’s about $2 million in current medical program; which is, what I will call, an abysmal program which was under Governor Chris Christie who-

TG Branfalt: Boo.

Beth Stavola: Yeah, he inherited it, and didn’t want it, and made it extremely difficult for the current six operators. There’s a lot of politicking going on in New Jersey right now. As you might imagine, the current six operators have suffered through a very difficult program. I have tremendous respect for them, but what we have to do is we have to increase the program. Six operators cannot handle a medical program and, certainly, not an adult use program in the state of New Jersey.

My personal thought is that there should be 100 dispensaries, 25 cultivations, and 25 production facilities. That goes with experience. That is what I’ve seen work and not work for both the patients and for the businesses. We have to have it be healthy for the businesses, but we can’t have it be monopolistic either, right? There’s certainly some politicking going on and quite a bit of pushback from the current operators. We’ll certainly figure that out as we go along.

I was just at a meeting today with regard to this and there were some state and local officials that were able to go on this trip that the NJCIA, we had all put together, to go to Nevada and actually listen to the Nevada politicians talk about how they did it and I believe that they did it right. Then this morning, we had a meeting in New Brunswick for any state and local politicians that could not end up taking that trip. Just to go over all of the issues and allow for them to ask industry experts questions. It was actually a really great meeting.

TG Branfalt: What sort of questions are lawmakers in New Jersey asking? We have reports from Colorado, we have reports from legal states, so what else can they be curious about at this point?

Beth Stavola: Well, one of the questions could be, “What do I tell my constituents when they say marijuana is a gateway drug?” My answer to that is I’ll tell you the flip side. I think marijuana is an exit drug and it’s an exit drug for a lot of people. We have an opioid crisis in this country. It’s an epidemic. We consume, as Americans, 85% of the opioids in the world. Yeah, unbelievable. It’s a major, major problem. I watch people get off of opioids and they’re smoking a vape pen.

Do you know the satisfaction that it gives you to watch a veteran who’s been just handed pill, after pill, after pill, prescription, after prescription from the VA, and have them just smoking a vape pen that’s not going to hurt them? I call it an exit drug and I think that really helps some of these local politicians to be able to go and talk to their constituents about it. All on my executive team, we’ve suggested, bring us to your local meetings. I’m a mom of six kids. I want to protect the kids, I want to make sure that we have childproof packaging, we’re not making things that are attractive to children. There’s a lot of things that go into it and I think it’s new territory. The politicians are really learning it as they go hand-in-hand with us.

TG Branfalt: In your opinion, what do you think legalization in New Jersey would mean for other east coast states, especially New York? You have Governor Andrew Cuomo of New York who has no interest in legalizing recreational cannabis use, but it’s hard for a lot of New Yorkers, people who are plugged in, to say that Cuomo’s going to let New Jersey reap all of the rewards from that industry. In your opinion, you operate in a variety of states, you live in New Jersey, which is very close to legalization, what does it mean for the east coast states if Jersey goes green?

Beth Stavola: Well, you know what? I think it’s really going to force Cuomo to go green, frankly, and I have heard some interviews that he is actually softening up to that. I think that the proof will be in the pudding when you’re actually seeing … I heard a statistic today that Colorado, which is, from a population standpoint, I think 3 million less residents than New Jersey, took $45 million worth of marijuana money and put it into the school system. New Jersey is so desperate for tax money and I’ve heard this joke, and it’s kind of scary, but people say, “Last one out of New Jersey, shut the lights out.” I know. It’s my hometown and it’s been so frustrating for me to see these marijuana programs that are very successful in these other states and see people helped, and come home, and see the same exact diseases, and not be able to help people here.

TG Branfalt: What exactly is holding the reforms back? You have a governor who is supportive of this. That’s not enough to push these lawmakers into supporting common sense recreational cannabis legislation?

Beth Stavola: Politics, politics, politics. There was, I will call him, an agitator, Assemblyman Joe Danielsen, who was at the meeting that I was at this morning and introduced himself as a firefighter. He was fighting back on the social reform piece as a wonderful, wonderful man, Leo Bridgewater, was speaking. Who was a decorated war vet with PTSD, who he’s just wonderful and a member of the NJCIA. Pushing back and it seemed like there was an agenda there. It could’ve been, in my opinion, to protect the six current operators and not allow for additional operators to come in.

TG Branfalt: It’s stunning to me, it really is. I want to talk to you about being a mother of six in this industry. Before we do that, we’ve got to take a break. This is the Ganjapreneur.com Podcast. I’m TG Branfalt.


At Ganjapreneur, we have heard from dozens of cannabis business owners who have encountered the issue of cannabias, which is when a mainstream business, whether a landlord, bank, or some other provider of vital business services refuses to do business with them simply because of their association with cannabis. We have even heard stories of businesses being unable to provide health and life insurance for their employees, because the insurance providers were too afraid to work with them.

We believe that this fear is totally unreasonable and that cannabis business owners deserve access to the same service and resources that other businesses are afforded, that they should be able to hire consultation to help them follow the letter of the law in their business endeavors, and that they should be able to provide employee benefits without needing to compromise on the quality of coverage they can offer. This is why we created the Ganjapreneur.com Business Service Director, a resource for cannabis professionals to find and connect with service providers who are cannabis friendly and who are actively seeking cannabis industry clients.

If you are considering hiring a business consultant, lawyer, accountant, web designer or any other ancillary service for your business, go to Ganjapreneur.com/Businesses to browse hundreds of agencies, firms, and organizations who support cannabis legalization and who want to help you grow your business. With so many options to choose from in each service category, you will be able to browse company profiles and do research on multiple companies in advance so you can find the providers who’s the best fit for your particular need.

Our Business Service Director is intended to be a useful and well maintained resource, which is why we individually vet each listing that is submitted. If you are a business service provider who wants to work with cannabis clients, you may be a good fit for our Service Directory. Go to Ganjapreneur.com/Businesses to create your profile and start connecting with cannabis entrepreneurs today.


TG Branfalt: Hey, welcome back to the Ganjapreneur.com Podcast. I’m your host, TG Branfalt, here with Beth Stavola. She’s the COO and Director of MPX Bioceutical Corporation and a member of the Board of Trustee of the New Jersey Cannabis Industry Association. She’s also a member of six, which is something I want to talk to you about. What is the reaction when … I don’t have any children. I tell people I work in the cannabis space and they’re like, “Oh, that’s cool.” What the reaction when you tell other parents what you do?

Beth Stavola: Six years ago, I didn’t. It was not popular, it was not cool, I was telling … Why are you flying to Arizona so much? Why are you flying to Nevada? I was buying commercial real estate. It was not a lie, I was buying commercial real estate, but I was also operating a medical marijuana business. I was concerned that other parents would do things like not let their children play with my children because, “You can’t play with Elle Stavola because her mom’s the pot mom.” Now, it’s very, very different. It’s like I get texts from all the kid’s parents. Like, “Happy 420…” It’s very different now, but what a difference six years makes. It’s still federally illegal and I’m not seeing a huge amount of movement in Congress. I’m hoping that’s going to change. I think that the kid’s parents are extremely supportive.

TG Branfalt: Can I ask? What the process was with your own children? I’m sure they know what you do, so do you mind telling me what that was like?

Beth Stavola: Whoa, that was interesting to say the least. My oldest two are 21 and 18 now. They were young teens and I walked them through the process. I actually took them out there. I explained to them what I was doing and it was kind of like a pharmacy. We were helping people that couldn’t be helped with other things, that didn’t want to take pills, that wanted to treat themselves naturally. Explaining to them that no one has ever died in the history of the world of a marijuana overdose, but people die of opioid overdoses all the time.

Their cousin died five years ago, my nephew, God rest his soul, of a heroin overdose. That was very painful for our family. The statistics speak for themselves, Tim. With a good medical program, you immediately see a reduction in opioid deaths of approximately 30%. I don’t know how anybody argues with these numbers. “The numbers don’t lie,” I say all the time.

TG Branfalt: How do you react to this fear mongering about legalization and the alleged negative effects it has on youth? A lot of parents with six children aren’t really as enlightened as you. I’m not trying to disparage anybody, but people who say, “Well, I have children, so we can’t legalize cannabis.” Right?

Beth Stavola: Well, it’s funny. There’s a lot of people that are reaching out to us in New Jersey that are saying, “Oh, we want to try to operate in New Jersey.” My husband’s best friend said to me that he’s had people come up to him and say, “I can’t believe what Beth Stavola’s doing. She’s really pushing this in our state and she should be ashamed of herself as a mother of six kids.” It runs the whole spectrum of people wanting to have me help them in the industry to telling me that I’m selling the Devil’s lettuce.

I think it’s really all about education and I think this fear mongering is because people just don’t know. They don’t know the statistics, they call it a gateway drug all the time, it is not. Talk to any teenage child right now. It is so much easier to get marijuana than it is to get alcohol. MPP slogan, it’s regulated adult use marijuana like alcohol. Tax it, regulate it, 21 and over.

TG Branfalt: You’re obviously very passionate, you’re very successful. I applaud your activism. You’re an activist on a daily level. You have to be, given the position that you’re in as a mother of a large family. What advice do you have for other entrepreneurs looking to either enter this space or those entrepreneurs who may want to get into the space in some capacity, but are worried about the effect that it could have on their family?

Beth Stavola: First off, the effect on your family is if you educate your family, they will get it. I know my parents had a really difficult time. I come from an extremely conservative background and, now, I have my mom running around her country club like, “Guess what Beth and Julie do.” Yeah. Like sending me articles about us. She’s so proud. She wants to be interviewed by you. Advice for entrepreneurs: check your ego at the door, don’t ask any of your employees to do anything that you wouldn’t do, share the wealth, there’s plenty to go around, and that’s important to me.

When I did the public deal, the most important thing to me was that every single one of my employees became an owner of this company. Each year they get stock options and, I have to say, everybody treats this company as an owner. Every cultivator, every janitor, every bud tender. You know what? I’ve given away a lot of my own money and my own stock. I would just say there’s a lot to go around, and pay it forward, and take care of the people that actually make the business successful. Greed is a very bad thing.

TG Branfalt: It’s a really incredible story. I really, really appreciate you taking the time, especially some of the personal stuff. Again, I don’t have any children, I don’t have that experience. Both of my parents used cannabis my entire childhood. I grew up it was fine, it was totally cool.

Beth Stavola: I love it.

TG Branfalt: Where can people find out more about you? Where can they find out more about your dispensaries, about MPX Bioceutical? Tell me where we’re going.

Beth Stavola: Yeah. [inaudible 00:33:12]. MPX Bioceutical.com. You could go on our website. We are traded on both OTC and the Canadian Stock Exchange. OTC is MPX, like Mary, Paul, Xavier, EF, like Elizabeth Frank. MPXEF. Then on the Canadian Stock Exchange it’s MPX.CN.

TG Branfalt: Again, I want to thank you for taking the time to come on the show. I know that you’re super busy. I really look forward to seeing just how you develop, how the company develops, and where you go from here. It’s a really, really incredible story and I thank you for sharing it.

Beth Stavola: Thank you so much. If anybody wants to follow us on Instagram, it’s @MPX_AZ. We have a lot of cool pictures and information-

TG Branfalt: I’ll check that out as well.

Beth Stavola: … On there.

TG Branfalt: You can find more episodes of the Ganjapreneur.com Podcast in the podcast section of the Ganjapreneur.com and in the Apple iTunes store. On the Ganjapreneur.com website, you will find the latest cannabis news and cannabis jobs updated daily along with transcripts of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play. This episode was engineered by TRIM Media House. I’ve been your host, TG Branfalt.

End